These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15201790)

  • 1. Low molecular weight heparin induced priapism.
    Lin PH; Bush RL; Lumsden AB
    J Urol; 2004 Jul; 172(1):263. PubMed ID: 15201790
    [No Abstract]   [Full Text] [Related]  

  • 2. Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma.
    Moore A; Lau E; Yang C; Mackool B; Kuter DJ
    Am J Clin Oncol; 2007 Jun; 30(3):329-31. PubMed ID: 17551316
    [No Abstract]   [Full Text] [Related]  

  • 3. [Priapism and low-molecular-weight heparin. Case report].
    Carmoi T; Skopinski S; Constans J; Vahedy A; Conri C
    Rev Med Interne; 2001 Oct; 22(10):1002-3. PubMed ID: 11695312
    [No Abstract]   [Full Text] [Related]  

  • 4. Anticoagulant-induced priapism progressing to penile gangrene: a devastating complication!
    Nagathan DS; Pahwa HS; Kumar A; Goel A
    BMJ Case Rep; 2012 Nov; 2012():. PubMed ID: 23175010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin.
    ten Berg MJ; van den Bemt PM; Huisman A; Schobben AF; Egberts TC; van Solinge WW
    Ann Pharmacother; 2009 Sep; 43(9):1405-12. PubMed ID: 19690229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acenocoumarol associated priapism: report of a case.
    Touloupidis S; Zoumpos I; Kalaitzis C; Vogiatzaki T; Chloropoulou P
    Andrologia; 2004 Feb; 36(1):47-9. PubMed ID: 14871265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
    Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
    Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
    Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
    J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices.
    Lee AY
    Dis Mon; 2005; 51(2-3):150-7. PubMed ID: 15900267
    [No Abstract]   [Full Text] [Related]  

  • 10. Malignancy-associated venous thrombosis with concurrent warfarin-induced skin necrosis, venous limb gangrene and thrombotic microangiopathy.
    Ng HJ; Crowther MA
    Thromb Haemost; 2006 Jun; 95(6):1038-9. PubMed ID: 16732387
    [No Abstract]   [Full Text] [Related]  

  • 11. Recall urticaria induced by skin tests with heparin.
    Weber HO; Fischer J; Kneilling M; Caroli U; Rocken M; Biedermann T
    Br J Dermatol; 2009 Jul; 161(1):187-9. PubMed ID: 19438465
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
    Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalteparin: new indication. Prophylaxis in medical patients: no advance.
    Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alopecia and dalteparin: a previously unreported association.
    Barnes C; Deidun D; Hynes K; Monagle P
    Blood; 2000 Aug; 96(4):1618-9. PubMed ID: 10979669
    [No Abstract]   [Full Text] [Related]  

  • 15. Dalteparin in critically ill patients.
    Smythe MA; Koerber JM
    N Engl J Med; 2011 Jul; 365(2):179-80; author reply 180. PubMed ID: 21751919
    [No Abstract]   [Full Text] [Related]  

  • 16. Delayed-type hypersensitivity to the ultra-low-molecular-weight heparin fondaparinux.
    Hohenstein E; Tsakiris D; Bircher AJ
    Contact Dermatitis; 2004 Sep; 51(3):149-51. PubMed ID: 15479206
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial.
    Kucher N; Leizorovicz A; Vaitkus PT; Cohen AT; Turpie AG; Olsson CG; Goldhaber SZ
    Arch Intern Med; 2005 Feb; 165(3):341-5. PubMed ID: 15710801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention of venous thromboembolism in internal medicine and neurology].
    Malý J; Dulícek P; Penka M; Malý R; Gumulec J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():63-7. PubMed ID: 16637452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.
    Agnelli G; Bergqvist D; Cohen AT; Gallus AS; Gent M;
    Br J Surg; 2005 Oct; 92(10):1212-20. PubMed ID: 16175516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of liposomal heparin spraygel as an add-on treatment in the management of superficial venous thrombosis.
    Katzenschlager R; Ugurlouglu A; Sipos G; Bihari I; Anyova EB; Hirschl M; Maruszynski M; Noszczyk W; Rybak Z; Cencora A
    Angiology; 2007; 58 Suppl 1():27S-35S. PubMed ID: 17478880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.